Co-founder & CSO. Belief BioMed (China): Leading development of China’s first potential gene therapy drug for hemophilia B, currently in Phase III
trials and nearing BLA submission.
Co-founder, AskBio and Bamboo Therapeutics (U.S.): Spearheaded advancements in AAV-based gene therapies.
Co-founder. Rui-ou (瑞) Charitable Foundation: Advancing rare disease research and translational medicine.
Academic & Professional Credentials
Ph.D., University of Pittsburgh (1992).
Distinguished Professor, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill.
Adjunct Professor, East China University of Science and Technology (Bioengineering/Pharmacy).
Board Member, American Society of Gene and Cell Therapy (ASGCT).
Lifetime Member. Chinese Society of Biologists.
NIH Grant Reviewer, Editorial Roles: Key journals in gene therapy
Research Impact
Focus : Gene delivery vectors and therapies for Duchenne muscular dystrophy, hemophilia, lysosomal storage disorders, and age-related diseases.
Publications: 230+ papers (*Nature, Science Translational Medicine*), 20,000+ citations. – Clinical Translation: Hemophilia B gene therapy drug (Phase
III) poised to become China’s first approved gene therapy for genetic disorders
Entrepreneurial Vision
Bridged academic research with commercialization, co-founding multiple biotech firms to accelerate gene therapy from lab to clinic.
Advocated for global collaboration in rare disease research through philanthropy and cross-border partnerships
Legacy :
A trailblazer in gene therapy, driving scientific innovation and equitable access to transformative treatments worldwide.
